A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Launched by BLUEFIN BIOMEDICINE, INC. · Jul 29, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medicine called BFB759 to see if it can help adults with moderate to severe atopic dermatitis, a common skin condition that causes itching and redness. The study will compare BFB759 to a placebo (a pill with no active medicine) to find out how well it works and how safe it is. Participants will be involved in the study for about 36 to 40 weeks, during which they will attend regular check-ups and follow specific instructions.

Adults between 18 and 75 years old who have had atopic dermatitis for at least a year and whose symptoms are not well controlled by usual skin treatments may be eligible to join. People with certain infections, immune problems, or who are pregnant or breastfeeding cannot take part. Those in the study should be willing to avoid certain medications and follow the study guidelines closely. This trial is currently recruiting participants of all genders who meet these criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Are adults (18-75) with a diagnosis of atopic dermatitis for at least one year.
• • Have moderate to severe disease not adequately controlled by topical treatments.
• • Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.
• Exclusion Criteria:
• • Have certain infections or other immune conditions.
• • Recently used medications that could interfere with the study.
• • Are pregnant or breastfeeding.